TLRY
Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.
Tilray Brands, Inc. (TLRY) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B); its weakest is Momentum (D). The rating has held at C for 7 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | C+ (2.5) | B (3.2) | C (2.4) | D (1.3) | C+ (2.6) | C (2.4) |
| 2026-11-08 | C (2.3) | B (3.2) | C (2.4) | D+ (1.6) | C+ (2.6) | C (2.4) |
| 2026-11-01 | C+ (2.5) | B (3.2) | C (2.4) | D (1.2) | C+ (2.7) | C (2.4) |
| 2026-10-25 | C (2.5) | B (3.2) | C (2.4) | D (1.4) | C+ (2.6) | C (2.4) |
| 2026-10-18 | C (2.4) | B (3.2) | C (2.4) | D (1.5) | C+ (2.6) | C (2.4) |